93 related articles for article (PubMed ID: 16060397)
1. Interferon-beta induction/interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C.
Kim KI; Sasase N; Taniguchi M; Mita K; Kinoshita K; Togitani T; Shikata M; Kimura N; Izawa S; Ohtani A; Nakao K; Muramoto Y; Kim SR; Nabeshima S; Ishii F; Tanaka K; Hayashi Y
Int J Clin Pharmacol Res; 2005; 25(2):71-6. PubMed ID: 16060397
[TBL] [Abstract][Full Text] [Related]
2. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
Asahina Y; Izumi N; Uchihara M; Noguchi O; Tsuchiya K; Hamano K; Kanazawa N; Itakura J; Miyake S; Sakai T
Hepatology; 2001 Aug; 34(2):377-84. PubMed ID: 11481623
[TBL] [Abstract][Full Text] [Related]
3. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection.
Jara P; Hierro L; de la Vega A; Díaz C; Camarena C; Frauca E; Miños-Bartolo G; Díez-Dorado R; de Guevara CL; Larrauri J; Rueda M
Pediatr Infect Dis J; 2008 Feb; 27(2):142-8. PubMed ID: 18174875
[TBL] [Abstract][Full Text] [Related]
5. Anti-viral actions and viral dynamics in the early phase of three different regimens of interferon treatment for chronic hepatitis C: differences between the twice-daily administration of interferon-beta treatment and the combination therapy with interferon-alpha plus ribavirin.
Nakajima H; Shimomura H; Iwasaki Y; Ikeda F; Umeoka F; Chengyu P; Taniguchi H; Ohnishi Y; Takagi SJ; Fujioka S; Shiratori Y
Acta Med Okayama; 2003 Oct; 57(5):217-25. PubMed ID: 14679399
[TBL] [Abstract][Full Text] [Related]
6. [Effect of ribavirin on dynamics of hepatitis C viremia in interferon alpha-treated patiens with response or no response].
Berg T; Kaul T; Naumann U; Wiedenmann B; Hopf U
Z Gastroenterol; 2000 Nov; 38(11):881-6. PubMed ID: 11132533
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
8. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis.
Derbala M; Amer A; Bener A; Lopez AC; Omar M; El Ghannam M
J Viral Hepat; 2005 Jul; 12(4):380-5. PubMed ID: 15985008
[TBL] [Abstract][Full Text] [Related]
9. Effect of combination therapy with ribavirin and high-dose interferon-alpha2b for 24 weeks in chronic hepatitis C.
Abe S; Narita R; Oto T; Tabaru A; Otsuki M
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):308-12. PubMed ID: 16460492
[TBL] [Abstract][Full Text] [Related]
10. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone.
Saracco G; Ciancio A; Olivero A; Smedile A; Roffi L; Croce G; Colletta C; Cariti G; Andreoni M; Biglino A; Calleri G; Maggi G; Tappero GF; Orsi PG; Terreni N; Macor A; Di Napoli A; Rinaldi E; Ciccone G; Rizzetto M
Hepatology; 2001 Jul; 34(1):133-8. PubMed ID: 11431744
[TBL] [Abstract][Full Text] [Related]
11. High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load.
Tsubota A; Arase Y; Suzuki F; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
J Gastroenterol; 2004; 39(2):155-61. PubMed ID: 15069622
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel defective HCV clones in liver transplant recipients with recurrent HCV infection.
Iwai A; Marusawa H; Takada Y; Egawa H; Ikeda K; Nabeshima M; Uemoto S; Chiba T
J Viral Hepat; 2006 Aug; 13(8):523-31. PubMed ID: 16901282
[TBL] [Abstract][Full Text] [Related]
13. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
[TBL] [Abstract][Full Text] [Related]
14. Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin for patients with chronic hepatitis C.
Furusyo N; Kubo N; Toyoda K; Takeoka H; Nabeshima S; Murata M; Nakamuta M; Hayashi J
Antiviral Res; 2005 Jul; 67(1):46-54. PubMed ID: 15913800
[TBL] [Abstract][Full Text] [Related]
15. 2'-,5'-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C.
Kim KI; Kim SR; Sasase N; Taniguchi M; Harada S; Kinoshita K; Kim SH; Akimoto Y; Shikata M; Kimura N; Izawa S; Ohtani A; Nakao K; Motojima M; Kinoshita M; Hirai M; Ohzu M; Hirooka T; Nabeshima S; Ishii F; Tanaka K; Hotta H
J Clin Pharm Ther; 2006 Oct; 31(5):441-6. PubMed ID: 16958821
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus free-virion and immune-complex dynamics during interferon therapy with and without ribavirin in genotype-1b chronic hepatitis C patients.
Fujita N; Kaito M; Tanaka H; Horiike S; Urawa N; Sugimoto R; Konishi M; Watanabe S; Adachi Y
J Viral Hepat; 2006 Mar; 13(3):190-8. PubMed ID: 16475995
[TBL] [Abstract][Full Text] [Related]
17. Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.
Tomimatsu M; Aizawa Y; Chuganji Y; Ishizuka H; Fujita Y; Aizawa R; Abe H; Matsuda T; Itou Y; Nakanishi H; Ushiyama H; Higuchi T; Fujimoto T; Endou H; Iga D; Ohta K; Kuroda H
J Gastroenterol Hepatol; 2006 Jul; 21(7):1177-83. PubMed ID: 16824072
[TBL] [Abstract][Full Text] [Related]
18. Prolonged negative HCV-RNA status led to a good outcome in chronic hepatitis C patients with genotype 1b and super-high viral load.
Kohno H; Aimitsu S; Kitamoto M; Aisaka Y; Kawakami H; Chayama K
Intervirology; 2006; 49(6):362-9. PubMed ID: 16926549
[TBL] [Abstract][Full Text] [Related]
19. Effects of ribavirin combined with interferon-alpha 2b on viral kinetics during first 12 weeks of treatment in patients with hepatitis C virus genotype 1 and high baseline viral loads.
Enomoto M; Nishiguchi S; Kohmoto M; Tamori A; Habu D; Takeda T; Seki S; Shiomi S
J Viral Hepat; 2004 Sep; 11(5):448-54. PubMed ID: 15357651
[TBL] [Abstract][Full Text] [Related]
20. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
Napoli N; Giannelli G; Antonaci A; Antonaci S
J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
